Live Breaking News & Updates on Nnounced Today That The Company Has Entered Intoa Clinical Collaboration Agreement With Msd Merck Amp Co

DAEJEON,South Korea, Dec. 12, 2022 /PRNewswire/ PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company has entered into a clinical collaboration agreement with MSD (Merck & Co., Inc., Rahway, NJ., USA), to initiate a Phase I combination trial of PMC-309, a novel anti-VISTA (V-domain Ig suppressor of T cell activation) antibody, in combination with KEYTRUDA (pembrolizumab), MSD's anti-PD-1 therapy. Under the terms of the agreement, PharmAbcine will sponsor a Phase I study in Australia to evaluate the safety and clinical efficacy of the combination therapy for the treatment of multiple advanced solid tumors, and MSD will supply KEYTRUDA. "We are excited to announce another pipeline combination project in collaboration with MSD besides olinvacimab, our lead anti-VEGFR2 antibody, undergoing a Phase II study in combination with KEYTRUDA in mTNBC (metastatic Tr ....

United States , Taejon Gwangyoksi , South Korea , Jin San Yoo , Business Development Team , Ir Pr Team , Pharmabcine Inc , Merck Co Inc , Merck Sharp Dohme , Prnewswire Pharmabcine Inc , Triple Negative Breast Cancer , Merck Sharp , V Domain Ig Suppressor , Myeloid Derived Suppressor Cells , Clinical Trial Application , Tumor Microenvironment , Age Related Macular Degeneration , Dec 12 , 022 Prnewswire Pharmabcine Inc Kosdaq 208340ks , A Clinical Stage Biotech Company Focusing On The Development Of Next Generation Antibody Therapeutics , Nnounced Today That The Company Has Entered Intoa Clinical Collaboration Agreement With Msd Merck Amp Co , O Initiatea Phasei Combination Trial Of Pmc 309 , A Novel Anti Vistav Domain Ig Suppressor Oft Cell Activation Antibody , N Combination With Keytruda Pembrolizumab , Sd 39s Anti Pd 1 Therapy Under The Terms Of Agreement , Harmabcine Will Sponsora Phasei Study In Australia To Evaluate The Safety And Clinical Efficacy Of Combination Therapy For Treatment Multiple Advanced Solid Tumors ,